Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/6/2024 | $133.00 | Equal Weight | Barclays |
| 8/7/2023 | $100.00 → $142.00 | Neutral → Buy | UBS |
| 11/1/2022 | $97.00 → $72.00 | Buy → Hold | Deutsche Bank |
| 10/31/2022 | $117.00 → $74.00 | Buy → Neutral | UBS |
| 8/19/2022 | $106.00 → $117.00 | Buy | UBS |
| 6/21/2022 | $110.00 → $90.00 | Underperform | BofA Securities |
| 1/5/2022 | $114.00 → $125.00 | Hold | Truist Securities |
| 10/29/2021 | $113.00 → $111.00 | Sector Perform | RBC Capital |
DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment," said Javier Rodriguez, CEO of DaVita. "Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond." Financial and operating highlights for the quarter and year ended December 31, 2025: Consolidated revenues were $3.620 billion
Partnership will accelerate Elara's growth and evolution as home health care leader; expand access to high-acuity care for complex diseases through new offerings Elara Caring (Elara), a leading national provider of skilled home health, hospice, behavioral health, and personal care services, today announced that it has entered into an agreement for a strategic investment from Ares' Private Equity Group (Ares) and DaVita. The investment is intended to expand access to personalized, clinically advanced care at home for patients with complex and acute needs. Elara will continue to operate as a wholly independent company led by CEO Ananth Mohan and the current management team. Following the cl
DENVER, Jan. 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Monday, February 2, 2026 at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Monday, February 2, 2026Starting at 5:00 p.m. ESTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00
UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously
Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously
8-K - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
SCHEDULE 13G/A - DAVITA INC. (0000927066) (Subject)
DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C
DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on
Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),
DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment," said Javier Rodriguez, CEO of DaVita. "Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond." Financial and operating highlights for the quarter and year ended December 31, 2025: Consolidated revenues were $3.620 billion
DENVER, Jan. 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Monday, February 2, 2026 at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Monday, February 2, 2026Starting at 5:00 p.m. ESTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen
DENVER, Oct. 29, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended September 30, 2025. "Our third quarter performance was in line with our expectations and keeps us on track to achieve our full-year guidance," said Javier Rodriguez, CEO of DaVita. "Our consistent focus on providing outstanding care is the key to these results, enabling us to continuously invest in improving the lives of our patients and supporting our dedicated teammates and physician partners." Financial and operating highlights for the quarter ended September 30, 2025: Consolidated revenues were $3.420 billion.Operating income was $506 million and adjusted operating
SC 13G/A - DAVITA INC. (0000927066) (Subject)
SC 13G/A - DAVITA INC. (0000927066) (Subject)
SC 13D/A - DAVITA INC. (0000927066) (Subject)